The recent activity involving Donald L. Reeves III, Senior Vice President of Outcomes at Itron, Inc., involved the disposition of company shares. On May 21, 2026, Mr. Reeves sold 255 shares of Itron's common stock. This sale amounted to a total value of $20,624, based on an execution price of $80.88 per share.
It is noteworthy that this transaction was executed under the parameters of a Rule 10b5-1 trading plan, which Mr. Reeves originally adopted on September 11, 2025. Following the sale of these shares, Donald L. Reeves III's direct holdings in Itron common stock total 29,419 shares.
The market context surrounding this divestiture is characterized by varied signals regarding Itron’s valuation and operational outlook. At the time of the reported sale, Itron shares were trading near their 52-week low of $77.77, while the stock was currently priced at $82.74. Despite these fluctuations, analysis from InvestingPro suggests that the stock may be undervalued at its current levels, citing a Price/Earnings (P/E) ratio of 13.17. Consequently, the company has been featured on InvestingPro’s list of Most Undervalued stocks.
Financial performance data presents a mixed picture for Itron. The corporation reported first-quarter earnings for 2026 that surpassed market expectations. Specifically, Itron achieved an Earnings Per Share (EPS) of $1.49, which was higher than the analyst projections of $1.23. Furthermore, revenue also exceeded forecasts, reaching $587 million when the anticipated figure was $572.09 million.
However, this positive financial reporting did not translate uniformly into immediate market sentiment. Despite these strong quarterly results, there was a discernible decline in the company’s stock during pre-market trading. This movement suggests that investor concern remains regarding specific performance aspects and the broader future outlook of Itron.
Analyst coverage further complicates the investment picture. In a separate development, Roth/MKM adjusted its price target for Itron. The firm lowered its previous estimate from $150 to $136, while simultaneously maintaining a 'Buy' rating on the stock. This downward revision of the price target was explicitly attributed by the firm to what it perceives as a more subdued near-term revenue growth trajectory for the company.
Roth/MKM further outlined that complex projects and transitory regulatory dynamics are influencing factors contributing to this revised outlook. These multiple, recent developments demonstrate a divergence in sentiment among both professional analysts and general investors regarding Itron’s financial stability and prospective growth path. The combination of robust quarterly earnings juxtaposed with analyst caution over near-term revenue signals creates an environment of mixed market reactions.